Depression treatment for Deerfield Beach — the full escalation pathway, 22 minutes away.

RECO Integrated Psychiatry is thirteen miles up A1A from Deerfield Beach — twenty-two minutes from The Cove or Pioneer Park to our Delray Beach office. Depression is treated on a documented algorithm: DSM-5-TR diagnosis, baseline PHQ-9, adequate SSRI or SNRI trial, evidence-based augmentation with aripiprazole, lithium, or T3, and a named escalation to TMS or Spravato at trial two if remission has not occurred. In-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS.

Deerfield Beach sits thirteen miles south of RECO Integrated Psychiatry’s Delray Beach office — twenty-two minutes up A1A or I-95, depending on the route. For adults whose depression has already survived a primary care SSRI trial, that short drive buys access to a psychiatrist-led escalation pathway without pulling the client out of work, family, or the routines that anchor daily functioning. This page describes what outpatient depression treatment looks like when it is done on a documented algorithm rather than one prescription at a time.

The diagnostic questions primary care doesn’t ask

Before treating “depression” as depression, the psychiatrist rules out bipolar spectrum illness. The MDQ and HCL-32 are standard screening instruments, but the diagnostic weight sits in a careful mood history — periods of decreased need for sleep with sustained productivity, family history of bipolar I or II, prior antidepressant-induced activation or hypomanic switch. Antidepressant monotherapy started in an unrecognized bipolar client is one of the more common pathways to a mixed state, rapid cycling, or a first manic episode, and it is largely preventable at intake.

Substance use screening (AUDIT-C, DAST-10), a thyroid panel with TSH and free T4, structured sleep history, and screening for OCD (Y-BOCS) and PTSD (PCL-5) all belong in the initial evaluation because each condition presents with the same low mood, low energy, low interest triad that gets coded as MDD. Undertreated OCD looks like depression; untreated obstructive sleep apnea looks like depression; subclinical hypothyroidism looks like depression. Layering a second antidepressant on top of an unrecognized primary condition rarely helps and usually gives the client a side-effect reason to stop.

RECO’s initial ninety-minute evaluation is structured around these decision points at intake — not at trial four, after the client has already burned through two medications and a year of appointments.

First-line pharmacotherapy done well

For a documented major depressive episode with no bipolar features, an SSRI (sertraline, escitalopram, fluoxetine) or an SNRI (venlafaxine XR, duloxetine) is the standard first move. Starting dose is titrated to therapeutic dose within two to four weeks — sertraline 50 mg to 100-200 mg, escitalopram 10 mg to 20 mg, venlafaxine XR 75 mg to 150-225 mg — and then held at therapeutic dose for a full six to eight week trial before response is judged against a repeat PHQ-9.

Selection is driven by presentation. Bupropion is first-line when sexual side effects, weight gain, or sedation would rule out an SSRI, and for clients with prominent anergia or comorbid tobacco use. Mirtazapine is a good fit for insomnia-predominant depression with weight loss. Duloxetine is often selected when neuropathic pain or fibromyalgia is comorbid. The selection matters less than the discipline of the trial — dose, duration, and documented PHQ-9 at baseline, four weeks, and eight weeks.

Adequate dose and adequate duration are what commercial payers require in the record before approving TMS or Spravato later. They are also, in practice, the two things that scattered treatment histories almost always lack. The RECO chart is written from the beginning as if a payer will read it — because eventually one will.

Augmentation and switching after partial response

A partial responder — a client whose PHQ-9 dropped from 22 to 14 on an adequate SSRI trial — is augmented before switching. Augmenting a working antidepressant carries a stronger evidence base than swapping to a new class, and it preserves the partial gain already achieved. First-line augmentation options are aripiprazole 2-15 mg, lithium titrated to an augmentation-range level of 0.4-0.8 mEq/L, or triiodothyronine (T3) 25-50 mcg. Bupropion augmentation is appropriate for residual anergia, low motivation, or SSRI-induced sexual side effects.

Second-line augmentation includes quetiapine XR 150-300 mg, the olanzapine-fluoxetine combination for the treatment-resistant indication, and buspirone for residual anxiety symptoms. Each requires baseline metabolic labs and a follow-up schedule that actually tracks weight, lipids, and HbA1c — and for lithium, renal function and TSH every six months.

For non-responders — no meaningful PHQ-9 movement on an adequate trial — a within-class switch (SSRI to SSRI) has weak evidence. A cross-class switch (SSRI to SNRI, or SSRI to bupropion, or SSRI to mirtazapine) has better evidence. RECO’s depression treatment algorithm names the switch and the interventional off-ramp at trial two, not at trial four.

The interventional escalation pathway

After two adequate antidepressant trials at adequate dose and duration have failed, the client meets DSM-5-TR criteria for treatment-resistant depression — and, critically, meets the threshold most commercial payers require for TMS or Spravato coverage. RECO’s protocol names the escalation option at trial two rather than at trial four or five, because clients who reach the third or fourth failed trial without a named escalation plan usually disengage from care entirely.

Repetitive TMS delivered at 120% of individually measured motor threshold to the left DLPFC — typically 3,000 pulses per session across a 36-session course — is the standard non-pharmacologic option and does not require the client to stop working, drive with a chaperone, or accept a cognitive side-effect burden. Spravato (intranasal esketamine), delivered in a REMS-monitored office setting, is the fit for clients who need a rapid-response option and can structure life around the two-hour post-dose monitoring window twice weekly during induction.

IV ketamine is available as a cash-pay option for clients on compressed schedules or those whose plan will not cover Spravato. Selection between the three is driven by clinical fit and life logistics, not by which modality generates the most reimbursement, and the escalation conversation is planned into the treatment plan — not improvised after another failed medication.

What to expect on your first visit

The initial appointment is a ninety-minute psychiatric evaluation with a psychiatrist or psychiatric mental health nurse practitioner. It covers the full mood history, prior medication trials at dose and duration, family psychiatric history, medical history and current medications, substance use screening, and structured screening for the differential diagnoses noted above. Baseline PHQ-9, GAD-7, MDQ, and PCL-5 are administered, and vitals and any needed labs are drawn or ordered.

The treatment plan is written the same day. If the client is starting a first antidepressant, dose, titration schedule, side-effect expectations, and follow-up cadence are documented in writing. If the client has already failed two adequate trials, the interventional conversation happens at visit one — not visit four. Follow-up is typically weekly to biweekly during titration and monthly once maintenance dosing is established.

Insurance and admissions from Deerfield Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS commercial plans for adult psychiatric services — the evaluation, medication management, TMS, and Spravato. Verification of benefits typically takes about ten minutes; out-of-network clients receive itemized superbills coded for reimbursement through their plan’s out-of-network psychiatric benefit.

The drive from Deerfield Beach neighborhoods — The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, Goldcoast Centre — is roughly thirteen miles up A1A or I-95, about twenty-two minutes midday. Same-week evaluations are typical, and TMS or Spravato workups run in parallel with the diagnostic evaluation when the referral history already documents treatment resistance.

Serving residents of: The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, Goldcoast Centre.